UnitedHealthcare Adds Two Genetic Test Codes to Its Prior Authorization List for October 2026
Short answer: UnitedHealthcare added two more CPT/PLA codes, 0648U and 0651U, to its genetic and molecular lab testing prior-authorization list effective October 1, 2026 — on top of ten codes added July 1, 2026. Labs and ordering clinicians must obtain authorization through the UnitedHealthcare Provider Portal before the date of service or the claim is denied outright, with no ability to balance-bill the member.
What changed, and when
UnitedHealthcare notified providers that new AMA-issued CPT Proprietary Laboratory Analyses (PLA) codes — 0648U and 0651U — join its genetic and molecular lab testing prior-authorization list starting October 1, 2026. UHC describes them as "either new codes from the AMA or codes that were previously designated as unproven," and the requirement applies across Neighborhood Health Partnership, UnitedHealthcare Level Funded, UnitedHealthcare Oxford, UnitedHealthcare of the River Valley, and UnitedHealthcare individual exchange plans in every state.
This is not an isolated update. UHC added ten other PLA codes to the same prior-authorization list on July 1, 2026: 0616U, 0618U, 0619U, 0622U, 0623U, 0624U, 0625U, 0626U, 0627U, and 0628U, under the identical plan scope. Between the two waves, UHC has added twelve genetic and molecular test codes to its prior-authorization requirements in a single AMA code cycle.
The consequence of missing it
UHC's policy is unambiguous about what happens when a lab or ordering provider skips the step: "If we don't receive a prior authorization request before the date of service, we'll deny the claim and you won't be able to balance bill members." That last clause matters for revenue-cycle planning — a missed authorization is not a delayed payment, it is a written-off claim with no path to recover the cost from the patient.
The codes sit inside UHC's broader Genetic and Molecular Lab Testing Notification/Prior Authorization Program, which already covers UHC commercial plans, individual exchange plans in every state except Colorado, and community (Medicaid managed care) plans in twenty states, including Florida, Texas, New York, Ohio, Pennsylvania, and Michigan. Providers verify whether a specific test requires authorization through the UnitedHealthcare Provider Portal and register the test in UHC's Genetic Test Registry before ordering or billing it — the commercial-payer equivalent of registering a test with a DEX Z-Code for Medicare.
Why UHC — and Medicare — are tightening the same year
The timing lines up with a federal push covered in our CRUSH rule explainer: CMS's Comprehensive Regulations to Uncover Suspicious Healthcare initiative, known as CRUSH, moved from a request for information in late February 2026 through a March 30, 2026 comment deadline to a proposed rule submitted to the White House Office of Management and Budget on August 7, 2026. The CMS Unified Agenda projects a notice of proposed rulemaking as early as October 2026 — the same month UHC's second wave of codes takes effect. The rule's central question is whether MolDX registration, currently required in 28 states, should become a nationwide prerequisite for billing molecular and genetic tests to Medicare.
Both moves trace back to the same spending picture. According to a Department of Health and Human Services Office of Inspector General analysis reported by Dark Daily in February 2026, Medicare Part B spending on clinical laboratory testing reached $8.4 billion in 2024, a 5% increase over 2023. Genetic tests made up only 5% of Part B test volume that year but consumed 43% of the dollars — $3.6 billion — while non-genetic testing spending has generally declined since 2021. Genetic testing expenditures climbed 20% between 2023 and 2024 alone, and the number of genetic tests paid under Part B grew 160% between 2018 and 2024, reaching 18 million tests in 2024 versus a 12% volume decline for non-genetic testing over the same period. Average Medicare spending per enrollee on genetic testing hit $794 in 2024, up 26% year over year, against roughly $200 per enrollee for non-genetic testing.
The regulatory timeline behind the payer tightening
Reading UHC's code additions alongside the federal calendar shows two enforcement tracks converging on the same few months rather than one isolated payer decision.
CRUSH is a Medicare-side initiative and UHC's code list is a commercial and exchange-plan policy, so they don't share a legal mechanism — but they share a target. Both are aimed at the same fast-growing, high-dollar category of testing, and both convert what used to be a documentation problem (proving medical necessity after the fact) into a pre-service gate (registering or authorizing the test before it's billed at all). For a lab or health system running the same test menu across Medicare, Medicare Advantage, and commercial UHC lives, that means the compliance calendar for a single test can now have two separate deadlines running in parallel.
What labs, RCM teams, and ordering clinicians should do now
With the October 1 effective date roughly three weeks out at time of publication, the practical checklist is short but time-sensitive. First, cross-reference your test menu's CPT/PLA codes against 0648U, 0651U, and the ten codes added in July — if any appear, confirm whether the specific patient's plan is one of the five UHC lines named in the notice. Second, build the prior-authorization step into intake for those tests now, not at go-live, since UHC's stated turnaround assumes the request lands before the date of service, not before the claim is filed. Third, register affected tests in UHC's Genetic Test Registry through the provider portal rather than relying on a payer representative to catch a missing authorization at claims review. Fourth, treat this as recurring maintenance: UHC has now updated this list twice in 2026, and each AMA PLA code release cycle is a plausible trigger for the next one. For the mechanics of building payer-ready documentation packets more broadly, see our prior-authorization guide for genetic testing; for how these commercial changes relate to Medicare's own coverage architecture, see our Medicare coverage overview.
FAQ
Which UnitedHealthcare plans require prior authorization for 0648U and 0651U?
Neighborhood Health Partnership, UnitedHealthcare Level Funded, UnitedHealthcare Oxford, UnitedHealthcare of the River Valley, and UnitedHealthcare individual exchange plans in every state, effective for dates of service on or after October 1, 2026, per UHC's provider notice.
What codes were added in the July 2026 wave?
Ten PLA codes: 0616U, 0618U, 0619U, 0622U, 0623U, 0624U, 0625U, 0626U, 0627U, and 0628U, effective July 1, 2026, across the same set of UHC plan types later joined by 0648U and 0651U in October.
What happens if a claim goes out without authorization?
UHC states the claim will be denied if the request isn't received before the date of service, and the provider cannot balance-bill the member for the denied amount — the cost is absorbed by the billing lab or ordering practice, not shifted to the patient.
Is this connected to the federal CRUSH rule at CMS?
Not directly — CRUSH is a Medicare policy under OMB review targeting MolDX registration, while UHC's list governs its own commercial and exchange plans. Both responded to the same underlying trend: genetic testing's outsized and fast-growing share of lab spending.
Where do labs check whether a specific test code needs authorization?
Through the UnitedHealthcare Provider Portal, under Prior Authorizations & Notifications, using a One Healthcare ID — the same portal used to register tests in UHC's Genetic Test Registry.
This article is provided for general educational and business-decision-support purposes for laboratory, revenue-cycle, and clinical-ordering professionals. It is not legal, coding, or reimbursement advice for any specific claim, and payer policies referenced here are subject to change; verify current requirements directly with UnitedHealthcare and CMS before making coverage or billing decisions. Consult qualified compliance, legal, or billing counsel for guidance specific to your organization.
Sources: UnitedHealthcare Provider News, "New AMA codes for genetic and molecular prior auth requirements" and "New genetic and molecular prior authorization codes" (uhcprovider.com, 2026); UnitedHealthcare, "Genetic and molecular lab testing prior authorization/advance notification" program page (uhcprovider.com); Discoveries in Health Policy, "CRUSH Reaches White House / OMB, Who Will Release the Proposed Regulations" (August 2026); Dark Daily, "Medicare Part B Lab Spending Hits $8.4 Billion as Genetic Testing Captures 43% of Dollars" (February 13, 2026), citing HHS Office of Inspector General analysis.